References
- Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007; 48: 56–64
- Caraglia M. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006; 13: 7–26
- Nastro E, Musolino C, Allegra A, Oteri G, Cicciù M, Alonci A, et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 206; 117: 181–187
- Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali F P, DiCosimo S, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005; 69: 35–43
- Fong G H, Klingensmith J, Wood C R, Rossant J, Breitman M L. Regulation of flt-1 expression during mouse embryogenesis suggests a role in the establishment of vascular endothelium. Dev Dyn 1996; 207: 1–10
- Dales J P, Garcia S, Bonnier P, Duffaud F, Carpentier S, Djemli A, et al. Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma. Ann Pathol 2003; 23: 297–305
- Hiratsuka S, Manu Y, Okada A, Seiki M, Noda T, Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001; 61: 1207–1213
- Gille H, Kowalski J, Yu L, Chen H, Pisabarro M T, Davis-Smith T, et al. A\repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinoisitol 3′-kinase activation and endothelial cell migration. EMBO J 2000; 19: 4064–4073
- Yang W, Arii S, Mori A, Furumoto K, Nakao T, Murata T, et al. sFlt-1 gene-transfected fibroblast: a wound-specific gene therapy inhibits local cancer recurrence. Cancer Res 2001; 61: 7840–7845
- Mahasreshti P J, Navarro J G, Kataram M, Wang M H, Carey D, Siegal G P, et al. Adenovirus-mediated soluble Flt-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001; 7: 2057–2066
- Harris A L, Reusch P, Barleon B, Hange, Dobbs N, Marme D. Soluble tie 2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001; 7: 1992–1997
- Byun J H, Park B W, Kim J R, Lee J H. Expression of vascular endothelial growth factor and its receptors after mandibular distraction osteogenesis. Int J Oral Maxillofac Surg 2007; 36: 338–344
- Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/flt-1): a dual regulator for angiogenesis. Angiogenesis 2006; 9: 225–230
- Ambati B K, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443: 993–997
- Allegra A, Oteri G, Nastro E, Alonci A, Bellomo G, DelFabro V, et al. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 2007, June 18 [Epub ahead of print]
- Vincenzi B, Santini D, Rocci L, Tonini G. Bisphosphonates: new antiangiogenic molecules in cancer treatment?. Ann Oncol 2003; 14: 806–807